首页> 外文OA文献 >Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

【2h】

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

机译：个性化精准药物在复发/难治性弥漫性大B细胞淋巴瘤中的新型药物靶点：全面综述

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma [J] . Falchi Lorenzo, Ferrajoli Alessandra, Jacobs Ira, Nature reviews Cancer . 2018,第8期

机译：对抗CD20抗体方案的基于证据审查，用于治疗复发或难治性慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤或滤泡淋巴瘤的患者
2. Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma [J] . Aaron Galaznik, Rachel Huelin, Michael Stokes, Future Science OA . 2018,第7期

机译：复发性或难治性弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤的治疗方法的系统评价
3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma [J] . Lorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, Clinical lymphoma, myeloma & leukemia . 2018,第8期

机译：对抗CD20抗体的含症患者的抗CD20抗体方案的基于循证审查，用于治疗复发或难治性慢性淋巴细胞白血病，弥漫性大B细胞淋巴瘤或滤泡淋巴瘤
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review [O] . Rosalba Camicia, Hans C. Winkler, Paul O. Hassa 2015

机译：个性化精准药物在复发/难治性弥漫性大B细胞淋巴瘤中的新型药物靶点：全面综述
7. 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma [O] . Thorsten Derlin, Christian Schultze-Florey, Rudolf A. Werner, 2020

机译：18F-FDG PET / CT在CD19-靶向嵌合抗原受体T细胞治疗中的嵌入式淋巴器官，用于复发或难治性弥漫性大B细胞淋巴瘤

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

著录项

引文网络

相似文献

相关主题

期刊订阅